3,980 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, Holdings Channel reports. The institutional investor bought 3,980 shares of the biopharmaceutical company’s stock, valued at approximately $1,198,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. California State Teachers Retirement System raised its position in shares of Alnylam Pharmaceuticals by 30,461.4% during the 2nd quarter. California State Teachers Retirement System now owns 60,164,157 shares of the biopharmaceutical company’s stock worth $18,111,216,000 after purchasing an additional 59,967,294 shares during the period. Wedmont Private Capital boosted its position in Alnylam Pharmaceuticals by 15.6% during the 2nd quarter. Wedmont Private Capital now owns 1,413 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 191 shares during the period. Saudi Central Bank grew its stake in Alnylam Pharmaceuticals by 90.4% during the 2nd quarter. Saudi Central Bank now owns 9,284 shares of the biopharmaceutical company’s stock worth $2,795,000 after buying an additional 4,408 shares during the last quarter. AlphaGrep UK Ltd acquired a new stake in Alnylam Pharmaceuticals in the second quarter worth $489,000. Finally, Raiffeisen Bank International AG increased its position in Alnylam Pharmaceuticals by 29.7% in the second quarter. Raiffeisen Bank International AG now owns 13,510 shares of the biopharmaceutical company’s stock worth $3,965,000 after buying an additional 3,097 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ALNY. Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a report on Friday, July 31st. Stifel Nicolaus dropped their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Wells Fargo & Company cut their price objective on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a research report on Friday, August 14th. Jefferies Financial Group boosted their target price on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a research note on Tuesday, September 8th. Finally, Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $376.67.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $248.68 on Friday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The business’s 50-day moving average price is $254.43 and its 200 day moving average price is $288.99. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The firm has a market cap of $33.28 billion, a P/E ratio of 46.22 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the company earned ($0.51) EPS. Alnylam Pharmaceuticals’s revenue was up 66.9% on a year-over-year basis. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).